Novocure to Report First Quarter 2026 Financial Results
Business Wire (Wed, 1-Apr 7:00 AM ET)
Business Wire (Thu, 26-Mar 7:00 AM ET)
Business Wire (Mon, 2-Mar 7:00 AM ET)
Novocure to Participate in 2026 Leerink Global Healthcare Conference
Business Wire (Fri, 27-Feb 4:30 PM ET)
Novocure Hits Revenue Milestones as FDA Approval of Optune Pax Expands Oncology Pipeline
Market Chameleon (Thu, 26-Feb 3:07 AM ET)
Novocure Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update
Business Wire (Thu, 26-Feb 7:00 AM ET)
Business Wire (Tue, 24-Feb 7:00 AM ET)
Market Chameleon (Thu, 12-Feb 5:31 AM ET)
U.S. FDA Approves Novocure's Optune Pax for the Treatment of Locally Advanced Pancreatic Cancer
Business Wire (Wed, 11-Feb 5:54 PM ET)
Novocure Hits Record Revenues and Expands Patient Reach—What’s Fueling This Growth?
Market Chameleon (Mon, 12-Jan 4:41 AM ET)
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.
Novocure Limited - trades on the NASDAQ stock market under the symbol NVCR.
As of April 15, 2026, NVCR stock price climbed to $11.75 with 120,362 million shares trading.
NVCR has a beta of 1.01, meaning it tends to be more sensitive to market movements. NVCR has a correlation of 0.06 to the broad based SPY ETF.
NVCR has a market cap of $1.32 billion. This is considered a Small Cap stock.
Last quarter Novocure Limited - reported $174 million in Revenue and -$.22 earnings per share. This beat revenue expectation by $1 million and exceeded earnings estimates by $.19.
In the last 3 years, NVCR traded as high as $83.60 and as low as $9.82.
The top ETF exchange traded funds that NVCR belongs to (by Net Assets): VTI, VB, IWM, VBK, VXF.
NVCR has underperformed the market in the last year with a return of -29.0%, while the SPY ETF gained +30.4%. In the last 3 month period, NVCR fell short of the market, returning -14.7%, while SPY returned +1.0%. However, in the most recent 2 weeks NVCR has outperformed the stock market by returning +7.8%, while SPY returned +6.9%.
NVCR support price is $10.87 and resistance is $11.73 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NVCR shares will trade within this expected range on the day.
